{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:12:58Z","timestamp":1788235978177,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100019287","name":"Barts Health NHS Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019287","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1136\/ijgc-2024-005394","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T01:00:14Z","timestamp":1725411614000},"page":"101853","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A multicenter retrospective study to assess feasibility, safety and efficacy of first-line carboplatin-paclitaxel versus carboplatin monotherapy in a frail, elderly epithelial ovarian cancer population\u2606"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1171-0593","authenticated-orcid":false,"given":"Eve","family":"Merry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronas Taner","family":"Kesmez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3799-3539","authenticated-orcid":false,"given":"Jonathan","family":"Ledermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Lockley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Macdonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibani","family":"Nicum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanthini","family":"Crusz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2400-1716","authenticated-orcid":false,"given":"Rowan","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2024-005394_bib1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","article-title":"Epidemiology of ovarian cancer: a review","volume":"14","author":"Reid","year":"2017","journal-title":"Cancer Biol Med"},{"key":"10.1136\/ijgc-2024-005394_bib2","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1136\/ijgc-2024-005394_bib3","unstructured":"Available: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/ovarian-cancer#heading-Zero."},{"key":"10.1136\/ijgc-2024-005394_bib4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.6004\/jnccn.2021.0007","article-title":"Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Armstrong","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1136\/ijgc-2024-005394_bib5","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","article-title":"Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial","volume":"374","author":"Katsumata","year":"2009","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2024-005394_bib6","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJMoa1505067","article-title":"Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer","volume":"374","author":"Chan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2024-005394_bib7","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","article-title":"Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial","volume":"15","author":"Pignata","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2024-005394_bib8","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(19)32259-7","article-title":"Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial","volume":"394","author":"Clamp","year":"2019","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2024-005394_bib9","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1200\/JCO.2004.02.175","article-title":"Enrollment of Elderly Patients in Clinical Trials for Cancer Drug Registration: A 7-Year Experience by the US Food and Drug Administration","volume":"22","author":"Talarico","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2024-005394_bib10","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1093\/annonc\/mdi367","article-title":"Non-enrolment of ovarian cancer patients in clinical trials: reasons and background","volume":"16","author":"Harter","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2024-005394_bib11","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1136\/ijgc-2018-000026","article-title":"Treatment decision-making in elderly women with ovarian cancer: an age- based comparison","volume":"29","author":"van Walree","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2024-005394_bib12","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1097\/IGC.0b013e31821bb700","article-title":"Clinical Trials and Treatment of the Elderly Diagnosed With Ovarian Cancer","volume":"21","author":"Freyer","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2024-005394_bib13","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(02)09738-6","article-title":"Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial","volume":"360","year":"2002","journal-title":"The Lancet"},{"key":"10.1136\/ijgc-2024-005394_bib14","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ygyno.2016.11.033","article-title":"Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - an NRG oncology\/Gynecologic Oncology Group study","volume":"144","author":"von Gruenigen","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005394_bib15","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/annonc\/mdl401","article-title":"Feasibility, toxicity and quality of life of first-line chemotherapy with platinum\/paclitaxel in elderly patients aged \u226570 years with advanced ovarian cancer\u2014a study by the AGO OVAR Germany","volume":"18","author":"Hilpert","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2024-005394_bib16","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology","volume":"36","author":"Mohile","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2024-005394_bib17","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","article-title":"International Society of Geriatric Oncology Consensus on Geriatric Assessment in Older Patients With Cancer","volume":"32","author":"Wildiers","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2024-005394_bib18","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ygyno.2017.07.126","article-title":"Functional not chronologic age: Frailty index predicts outcomes in advanced ovarian cancer","volume":"147","author":"Kumar","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005394_bib19","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jamda.2013.03.022","article-title":"Frailty consensus: a call to action","volume":"14","author":"Morley","year":"2013","journal-title":"J Am Med Dir Assoc"},{"key":"10.1136\/ijgc-2024-005394_bib20","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1093\/annonc\/mdt360","article-title":"Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial","volume":"24","author":"Falandry","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2024-005394_bib21","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1503\/cmaj.050051","article-title":"A global clinical measure of fitness and frailty in elderly people","volume":"173","author":"Rockwood","year":"2005","journal-title":"Can Med Assoc J"},{"key":"10.1136\/ijgc-2024-005394_bib22","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jamaoncol.2021.0696","article-title":"Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A GINECO\/GCIG Randomized Clinical Trial","volume":"7","author":"Falandry","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1136\/ijgc-2024-005394_bib23","unstructured":"MDCalc. Charlson comorbidity index. n.d. Available: https:\/\/www.mdcalc.com\/calc\/3917\/charlson-comorbidity-index-cci."},{"key":"10.1136\/ijgc-2024-005394_bib24","article-title":"Can Vulnerable Elders Survey-13 predict the impact of frailty on chemotherapy in elderly patients with gynaecological malignancies?","volume":"97","author":"Ferrero","year":"2018","journal-title":"Medicine (Abingdon)"},{"key":"10.1136\/ijgc-2024-005394_bib25","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1093\/annonc\/mdi368","article-title":"Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study","volume":"16","author":"Freyer","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2024-005394_bib26","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ygyno.2019.02.015","article-title":"Early treatment modifications improve chemotherapy adherence in ovarian cancer patients \u226570 years","volume":"153","author":"Heilmann","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005394_bib27","doi-asserted-by":"crossref","first-page":"227","DOI":"10.14694\/EdBook_AM.2013.33.227","article-title":"Treatment and Trials: Ovarian Cancer in Older Women","volume":"33","author":"Freyer","year":"2013","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1136\/ijgc-2024-005394_bib28","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jgo.2022.04.008","article-title":"Geriatric assessment in the management of older patients with cancer - a systematic review (update)","volume":"13","author":"Hamaker","year":"2022","journal-title":"J Geriatr Oncol"},{"key":"10.1136\/ijgc-2024-005394_bib29","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1200\/JCO.2010.34.1552","article-title":"Completion of Adjuvant Chemotherapy and Use of Health Services for Older Women With Epithelial Ovarian Cancer","volume":"29","author":"Fairfield","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2024-005394_bib30","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1200\/JCO.21.00089","article-title":"Geriatric Assessment and Management in Cancer","volume":"39","author":"Rostoft","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2024-005394_bib31","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.leukres.2013.12.018","article-title":"The relevance of a geriatric assessment for elderly patients with a haematological malignancy--a systematic review","volume":"38","author":"Hamaker","year":"2014","journal-title":"Leuk Res"},{"key":"10.1136\/ijgc-2024-005394_bib32","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1200\/JCO.2002.20.2.494","article-title":"Comprehensive Geriatric Assessment Adds Information to Eastern Cooperative Oncology Group Performance Status in Elderly Cancer Patients: An Italian Group for Geriatric Oncology Study","volume":"20","author":"Repetto","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2024-005394_bib33","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.1016\/S2666-7568(22)00002-2","article-title":"Validation of the geriatric vulnerability score in older patients with ovarian cancer: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study","volume":"3","author":"Falandry","year":"2022","journal-title":"Lancet Healthy Longevity"},{"key":"10.1136\/ijgc-2024-005394_bib34","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-024485","article-title":"Clinical and cost-effectiveness of a comprehensive geriatric assessment and management for Canadian elders with cancer - the 5C study: a study protocol for a randomised controlled phase III trial","volume":"9","author":"Puts","year":"2019","journal-title":"BMJ Open"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25009727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25009727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2024-005394","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:13:26Z","timestamp":1788232406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25009727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1048891X25009727"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2024-005394","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multicenter retrospective study to assess feasibility, safety and efficacy of first-line carboplatin-paclitaxel versus carboplatin monotherapy in a frail, elderly epithelial ovarian cancer population\u2606","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2024-005394","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101853"}}